Phase I, Open-label, Non-randomized Study to Evaluate Safety of BC2059
Status:
Active, not recruiting
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
Phase I, open-label, non-randomized study to evaluate safety of BC2059 administered
intravenously to subjects with proven primary or recurrent desmoid tumor that is unresectable
and symptomatic or progressive.
Phase:
Phase 1
Details
Lead Sponsor:
Beta Cat Pharmaceuticals, Inc. Iterion Therapeutics